Dataset Information

A positron emission tomography occupancy study of brexpiprazole at dopamine D₂ and D₃ and serotonin 5-HT_1A and 5-HT_2A receptors, and serotonin reuptake transporters in subjects with schizophrenia.

ABSTRACT: The objective of this study (NCT01854944) was to assess D₂/D₃, 5-HT_1A, 5-HT_2A and serotonin transporter (SERT) occupancies of brexpiprazole in adult subjects with schizophrenia in order to identify the in vivo pharmacologic profile that may be relevant to the antipsychotic, antidepressant, and side effect profiles of the drug. Subjects were grouped into three independent cohorts of four subjects each. All subjects underwent positron emission tomography (PET) scans with two different radiotracers at baseline prior to brexpiprazole administration, and again on Day 10 after daily doses of either 4 mg (Cohorts 1 and 2), or 1 mg (Cohort 3). Cohort 1 received scans with [¹¹C]-(+)-PHNO to measure D₂ and D₃ receptor occup

SUBMITTER: Girgis RR

PROVIDER: S-EPMC7075883 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

A positron emission tomography occupancy study of brexpiprazole at dopamine D₂ and D₃ and serotonin 5-HT_1A and 5-HT_2A receptors, and serotonin reuptake transporters in subjects with schizophrenia.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia.

OmicsDI is part of the ELIXIR infrastructure

Tweets

A positron emission tomography occupancy study of brexpiprazole at dopamine D₂ and D₃ and serotonin 5-HT_1A and 5-HT_2A receptors, and serotonin reuptake transporters in subjects with schizophrenia.